HA-330 hemoadsorption in septic shock requiring high-dose norepinephrine: a multicenter randomized controlled trial (CLEANSE)
- terminated early at second pre-planned interim analysis
Authors' conclusion
In this randomized trial which was terminated early, adjunctive hemoadsorption with HA-330 in patients with septic shock requiring high-dose vasopressors did not statistically reduce 28-day mortality.
Study context
- Population
- Patients with septic shock requiring norepinephrine ≥ 0.2 mcg/kg/min at two tertiary care centres in Thailandplanned 206
- Participants
- 128 patients
- Comparison
- HA vs ST
- HAn = 63
- STn = 65reference
- Primary endpoint
- 28-day mortality
- Follow-up
- 28 days
Methodological detailsmulticentre
- Multicentre
Primary result
As reported in the abstract
day 28
Each group vs STEstimate (95% CI)P value
HA
RR 0.76(0.54–1.07)
P = 0.16HA
HR 0.68(0.44–1.07)
P = 0.09Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| 28-day mortality, adjusted for IL-6 (log-transformed) and VIS at hour 0 (post-hoc Cox model) · post-hoc · post-hoc analysis | 0.62 (0.39–0.97) | P = 0.037 | |
| 0.20.5125Hazard ratio (log scale) |
Organ support-free days, shock reversal, vasopressor doses, inflammatory markers
- No significant differences
Safety
Events
| Outcome | HA | ST |
|---|---|---|
| Serious adverse events | 0 | 0 |
Original publication
HA-330 hemoadsorption in septic shock requiring high-dose norepinephrine: a multicenter randomized controlled trial (CLEANSE). Crit Care. Published 11 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →